nodes	percent_of_prediction	percent_of_DWPC	metapath
Montelukast—CYP2A6—Progesterone—uterine cancer	0.166	0.23	CbGbCtD
Montelukast—CYP2C8—Medroxyprogesterone Acetate—uterine cancer	0.123	0.171	CbGbCtD
Montelukast—CYP2C9—Medroxyprogesterone Acetate—uterine cancer	0.0859	0.119	CbGbCtD
Montelukast—CYP2C8—Progesterone—uterine cancer	0.0816	0.113	CbGbCtD
Montelukast—PTGS1—Etoposide—uterine cancer	0.0633	0.0878	CbGbCtD
Montelukast—CYP2C9—Progesterone—uterine cancer	0.0569	0.079	CbGbCtD
Montelukast—CYP3A4—Medroxyprogesterone Acetate—uterine cancer	0.05	0.0693	CbGbCtD
Montelukast—CYP2C8—Etoposide—uterine cancer	0.0365	0.0507	CbGbCtD
Montelukast—CYP3A4—Progesterone—uterine cancer	0.0331	0.0459	CbGbCtD
Montelukast—CYP3A4—Etoposide—uterine cancer	0.0148	0.0205	CbGbCtD
Montelukast—CYP3A4—Doxorubicin—uterine cancer	0.0101	0.014	CbGbCtD
Montelukast—PTGS1—oviduct—uterine cancer	0.0039	0.0664	CbGeAlD
Montelukast—CYSLTR1—smooth muscle tissue—uterine cancer	0.00388	0.0661	CbGeAlD
Montelukast—CYSLTR1—mammalian vulva—uterine cancer	0.0035	0.0595	CbGeAlD
Montelukast—CYSLTR1—uterus—uterine cancer	0.00333	0.0567	CbGeAlD
Montelukast—CYSLTR1—female reproductive system—uterine cancer	0.00299	0.051	CbGeAlD
Montelukast—CYSLTR1—vagina—uterine cancer	0.00271	0.0461	CbGeAlD
Montelukast—PTGS1—artery—uterine cancer	0.00258	0.044	CbGeAlD
Montelukast—ALOX5—smooth muscle tissue—uterine cancer	0.00235	0.0401	CbGeAlD
Montelukast—ALOX5—decidua—uterine cancer	0.0023	0.0393	CbGeAlD
Montelukast—ALOX5—female reproductive system—uterine cancer	0.00181	0.0309	CbGeAlD
Montelukast—SLCO2B1—decidua—uterine cancer	0.00177	0.0302	CbGeAlD
Montelukast—CYSLTR1—lymph node—uterine cancer	0.00175	0.0298	CbGeAlD
Montelukast—SLCO2B1—renal system—uterine cancer	0.00174	0.0297	CbGeAlD
Montelukast—ALOX5—female gonad—uterine cancer	0.00165	0.0281	CbGeAlD
Montelukast—SLCO2B1—uterus—uterine cancer	0.00155	0.0264	CbGeAlD
Montelukast—CYP2A6—vagina—uterine cancer	0.00145	0.0246	CbGeAlD
Montelukast—SLCO2B1—female reproductive system—uterine cancer	0.0014	0.0238	CbGeAlD
Montelukast—SLCO2B1—female gonad—uterine cancer	0.00127	0.0216	CbGeAlD
Montelukast—CYP2C8—renal system—uterine cancer	0.00112	0.0191	CbGeAlD
Montelukast—CYP2C8—endometrium—uterine cancer	0.00108	0.0185	CbGeAlD
Montelukast—ALOX5—lymph node—uterine cancer	0.00106	0.0181	CbGeAlD
Montelukast—PTGS1—epithelium—uterine cancer	0.000979	0.0167	CbGeAlD
Montelukast—PTGS1—uterine cervix—uterine cancer	0.000971	0.0165	CbGeAlD
Montelukast—PTGS1—smooth muscle tissue—uterine cancer	0.000944	0.0161	CbGeAlD
Montelukast—PTGS1—renal system—uterine cancer	0.000908	0.0155	CbGeAlD
Montelukast—CYP2C8—female reproductive system—uterine cancer	0.000897	0.0153	CbGeAlD
Montelukast—PTGS1—endometrium—uterine cancer	0.000878	0.015	CbGeAlD
Montelukast—PTGS1—mammalian vulva—uterine cancer	0.00085	0.0145	CbGeAlD
Montelukast—SLCO2B1—lymph node—uterine cancer	0.000816	0.0139	CbGeAlD
Montelukast—CYP2C8—vagina—uterine cancer	0.000811	0.0138	CbGeAlD
Montelukast—PTGS1—uterus—uterine cancer	0.000809	0.0138	CbGeAlD
Montelukast—CYP2C9—female reproductive system—uterine cancer	0.000797	0.0136	CbGeAlD
Montelukast—CYP3A4—renal system—uterine cancer	0.000759	0.0129	CbGeAlD
Montelukast—PTGS1—female reproductive system—uterine cancer	0.000728	0.0124	CbGeAlD
Montelukast—PTGS1—female gonad—uterine cancer	0.000662	0.0113	CbGeAlD
Montelukast—PTGS1—vagina—uterine cancer	0.000658	0.0112	CbGeAlD
Montelukast—CYP3A4—female reproductive system—uterine cancer	0.000608	0.0104	CbGeAlD
Montelukast—Bone disorder—Epirubicin—uterine cancer	0.000562	0.00263	CcSEcCtD
Montelukast—Somnolence—Progesterone—uterine cancer	0.000562	0.00263	CcSEcCtD
Montelukast—Nervous system disorder—Medroxyprogesterone Acetate—uterine cancer	0.000561	0.00263	CcSEcCtD
Montelukast—Thrombocytopenia—Medroxyprogesterone Acetate—uterine cancer	0.000561	0.00263	CcSEcCtD
Montelukast—Liver injury—Doxorubicin—uterine cancer	0.000558	0.00262	CcSEcCtD
Montelukast—Dyspepsia—Progesterone—uterine cancer	0.000556	0.0026	CcSEcCtD
Montelukast—Skin disorder—Medroxyprogesterone Acetate—uterine cancer	0.000556	0.0026	CcSEcCtD
Montelukast—Gastrointestinal disorder—Progesterone—uterine cancer	0.000545	0.00255	CcSEcCtD
Montelukast—Fatigue—Progesterone—uterine cancer	0.000545	0.00255	CcSEcCtD
Montelukast—Pain—Progesterone—uterine cancer	0.00054	0.00253	CcSEcCtD
Montelukast—Musculoskeletal discomfort—Medroxyprogesterone Acetate—uterine cancer	0.000522	0.00244	CcSEcCtD
Montelukast—Viral infection—Doxorubicin—uterine cancer	0.00052	0.00244	CcSEcCtD
Montelukast—Bone disorder—Doxorubicin—uterine cancer	0.00052	0.00244	CcSEcCtD
Montelukast—Insomnia—Medroxyprogesterone Acetate—uterine cancer	0.000518	0.00243	CcSEcCtD
Montelukast—Gastrointestinal pain—Progesterone—uterine cancer	0.000517	0.00242	CcSEcCtD
Montelukast—Paraesthesia—Medroxyprogesterone Acetate—uterine cancer	0.000514	0.00241	CcSEcCtD
Montelukast—Pneumonia—Etoposide—uterine cancer	0.00051	0.00239	CcSEcCtD
Montelukast—Somnolence—Medroxyprogesterone Acetate—uterine cancer	0.000509	0.00238	CcSEcCtD
Montelukast—Hepatocellular injury—Epirubicin—uterine cancer	0.000508	0.00238	CcSEcCtD
Montelukast—Infestation NOS—Etoposide—uterine cancer	0.000507	0.00237	CcSEcCtD
Montelukast—Infestation—Etoposide—uterine cancer	0.000507	0.00237	CcSEcCtD
Montelukast—Dyspepsia—Medroxyprogesterone Acetate—uterine cancer	0.000504	0.00236	CcSEcCtD
Montelukast—Stevens-Johnson syndrome—Etoposide—uterine cancer	0.000502	0.00235	CcSEcCtD
Montelukast—Urticaria—Progesterone—uterine cancer	0.000502	0.00235	CcSEcCtD
Montelukast—Abdominal pain—Progesterone—uterine cancer	0.000499	0.00234	CcSEcCtD
Montelukast—Body temperature increased—Progesterone—uterine cancer	0.000499	0.00234	CcSEcCtD
Montelukast—Neuropathy peripheral—Etoposide—uterine cancer	0.000497	0.00233	CcSEcCtD
Montelukast—Gastrointestinal disorder—Medroxyprogesterone Acetate—uterine cancer	0.000494	0.00231	CcSEcCtD
Montelukast—Jaundice—Etoposide—uterine cancer	0.000494	0.00231	CcSEcCtD
Montelukast—Fatigue—Medroxyprogesterone Acetate—uterine cancer	0.000494	0.00231	CcSEcCtD
Montelukast—Hepatobiliary disease—Etoposide—uterine cancer	0.000479	0.00224	CcSEcCtD
Montelukast—Neuropathy—Epirubicin—uterine cancer	0.000477	0.00223	CcSEcCtD
Montelukast—Hepatocellular injury—Doxorubicin—uterine cancer	0.00047	0.0022	CcSEcCtD
Montelukast—Gastrointestinal pain—Medroxyprogesterone Acetate—uterine cancer	0.000468	0.00219	CcSEcCtD
Montelukast—Myalgia—Dactinomycin—uterine cancer	0.000466	0.00218	CcSEcCtD
Montelukast—Hypersensitivity—Progesterone—uterine cancer	0.000466	0.00218	CcSEcCtD
Montelukast—Urticaria—Medroxyprogesterone Acetate—uterine cancer	0.000455	0.00213	CcSEcCtD
Montelukast—Asthenia—Progesterone—uterine cancer	0.000453	0.00212	CcSEcCtD
Montelukast—Hypoaesthesia—Etoposide—uterine cancer	0.000453	0.00212	CcSEcCtD
Montelukast—Abdominal pain—Medroxyprogesterone Acetate—uterine cancer	0.000453	0.00212	CcSEcCtD
Montelukast—Body temperature increased—Medroxyprogesterone Acetate—uterine cancer	0.000453	0.00212	CcSEcCtD
Montelukast—Urinary tract disorder—Etoposide—uterine cancer	0.000449	0.0021	CcSEcCtD
Montelukast—Pruritus—Progesterone—uterine cancer	0.000447	0.00209	CcSEcCtD
Montelukast—Oedema—Dactinomycin—uterine cancer	0.000447	0.00209	CcSEcCtD
Montelukast—Urethral disorder—Etoposide—uterine cancer	0.000446	0.00209	CcSEcCtD
Montelukast—Infection—Dactinomycin—uterine cancer	0.000444	0.00208	CcSEcCtD
Montelukast—Neuropathy—Doxorubicin—uterine cancer	0.000441	0.00207	CcSEcCtD
Montelukast—Thrombocytopenia—Dactinomycin—uterine cancer	0.000437	0.00205	CcSEcCtD
Montelukast—Diarrhoea—Progesterone—uterine cancer	0.000432	0.00202	CcSEcCtD
Montelukast—Erythema multiforme—Etoposide—uterine cancer	0.00043	0.00201	CcSEcCtD
Montelukast—PTGS1—lymph node—uterine cancer	0.000426	0.00725	CbGeAlD
Montelukast—Cardiac disorder—Etoposide—uterine cancer	0.000422	0.00198	CcSEcCtD
Montelukast—Hypersensitivity—Medroxyprogesterone Acetate—uterine cancer	0.000422	0.00198	CcSEcCtD
Montelukast—Dizziness—Progesterone—uterine cancer	0.000418	0.00196	CcSEcCtD
Montelukast—Immune system disorder—Etoposide—uterine cancer	0.000411	0.00192	CcSEcCtD
Montelukast—Asthenia—Medroxyprogesterone Acetate—uterine cancer	0.000411	0.00192	CcSEcCtD
Montelukast—Eczema—Epirubicin—uterine cancer	0.00041	0.00192	CcSEcCtD
Montelukast—Mediastinal disorder—Etoposide—uterine cancer	0.00041	0.00192	CcSEcCtD
Montelukast—Musculoskeletal discomfort—Dactinomycin—uterine cancer	0.000407	0.00191	CcSEcCtD
Montelukast—Pruritus—Medroxyprogesterone Acetate—uterine cancer	0.000405	0.0019	CcSEcCtD
Montelukast—Vomiting—Progesterone—uterine cancer	0.000402	0.00188	CcSEcCtD
Montelukast—Rash—Progesterone—uterine cancer	0.000398	0.00187	CcSEcCtD
Montelukast—Dermatitis—Progesterone—uterine cancer	0.000398	0.00186	CcSEcCtD
Montelukast—Headache—Progesterone—uterine cancer	0.000396	0.00185	CcSEcCtD
Montelukast—Diarrhoea—Medroxyprogesterone Acetate—uterine cancer	0.000392	0.00183	CcSEcCtD
Montelukast—Fatigue—Dactinomycin—uterine cancer	0.000385	0.0018	CcSEcCtD
Montelukast—Pain—Dactinomycin—uterine cancer	0.000382	0.00179	CcSEcCtD
Montelukast—Muscle spasms—Etoposide—uterine cancer	0.000381	0.00178	CcSEcCtD
Montelukast—Eczema—Doxorubicin—uterine cancer	0.00038	0.00178	CcSEcCtD
Montelukast—Dizziness—Medroxyprogesterone Acetate—uterine cancer	0.000379	0.00177	CcSEcCtD
Montelukast—Nausea—Progesterone—uterine cancer	0.000375	0.00176	CcSEcCtD
Montelukast—Gastrointestinal pain—Dactinomycin—uterine cancer	0.000365	0.00171	CcSEcCtD
Montelukast—Vomiting—Medroxyprogesterone Acetate—uterine cancer	0.000364	0.0017	CcSEcCtD
Montelukast—Rash—Medroxyprogesterone Acetate—uterine cancer	0.000361	0.00169	CcSEcCtD
Montelukast—Dermatitis—Medroxyprogesterone Acetate—uterine cancer	0.000361	0.00169	CcSEcCtD
Montelukast—Headache—Medroxyprogesterone Acetate—uterine cancer	0.000359	0.00168	CcSEcCtD
Montelukast—Body temperature increased—Dactinomycin—uterine cancer	0.000353	0.00165	CcSEcCtD
Montelukast—Abdominal pain—Dactinomycin—uterine cancer	0.000353	0.00165	CcSEcCtD
Montelukast—Cough—Etoposide—uterine cancer	0.000346	0.00162	CcSEcCtD
Montelukast—Convulsion—Etoposide—uterine cancer	0.000343	0.00161	CcSEcCtD
Montelukast—Nausea—Medroxyprogesterone Acetate—uterine cancer	0.00034	0.00159	CcSEcCtD
Montelukast—Unspecified disorder of skin and subcutaneous tissue—Etoposide—uterine cancer	0.000335	0.00157	CcSEcCtD
Montelukast—Toxic epidermal necrolysis—Epirubicin—uterine cancer	0.000332	0.00155	CcSEcCtD
Montelukast—Aspartate aminotransferase increased—Epirubicin—uterine cancer	0.000332	0.00155	CcSEcCtD
Montelukast—Nasopharyngitis—Epirubicin—uterine cancer	0.00033	0.00154	CcSEcCtD
Montelukast—Hypersensitivity—Dactinomycin—uterine cancer	0.000329	0.00154	CcSEcCtD
Montelukast—Alanine aminotransferase increased—Epirubicin—uterine cancer	0.000325	0.00152	CcSEcCtD
Montelukast—Anaphylactic shock—Etoposide—uterine cancer	0.000323	0.00151	CcSEcCtD
Montelukast—Infection—Etoposide—uterine cancer	0.000321	0.0015	CcSEcCtD
Montelukast—Asthenia—Dactinomycin—uterine cancer	0.00032	0.0015	CcSEcCtD
Montelukast—Asthma—Epirubicin—uterine cancer	0.000319	0.00149	CcSEcCtD
Montelukast—Influenza—Epirubicin—uterine cancer	0.000319	0.00149	CcSEcCtD
Montelukast—Thrombocytopenia—Etoposide—uterine cancer	0.000316	0.00148	CcSEcCtD
Montelukast—Eosinophilia—Epirubicin—uterine cancer	0.000315	0.00148	CcSEcCtD
Montelukast—Skin disorder—Etoposide—uterine cancer	0.000314	0.00147	CcSEcCtD
Montelukast—Pancreatitis—Epirubicin—uterine cancer	0.000312	0.00146	CcSEcCtD
Montelukast—Toxic epidermal necrolysis—Doxorubicin—uterine cancer	0.000307	0.00144	CcSEcCtD
Montelukast—Aspartate aminotransferase increased—Doxorubicin—uterine cancer	0.000307	0.00144	CcSEcCtD
Montelukast—Bronchitis—Epirubicin—uterine cancer	0.000306	0.00143	CcSEcCtD
Montelukast—Diarrhoea—Dactinomycin—uterine cancer	0.000306	0.00143	CcSEcCtD
Montelukast—Nasopharyngitis—Doxorubicin—uterine cancer	0.000305	0.00143	CcSEcCtD
Montelukast—Alanine aminotransferase increased—Doxorubicin—uterine cancer	0.000301	0.00141	CcSEcCtD
Montelukast—Upper respiratory tract infection—Epirubicin—uterine cancer	0.000296	0.00139	CcSEcCtD
Montelukast—Asthma—Doxorubicin—uterine cancer	0.000295	0.00138	CcSEcCtD
Montelukast—Influenza—Doxorubicin—uterine cancer	0.000295	0.00138	CcSEcCtD
Montelukast—Eosinophilia—Doxorubicin—uterine cancer	0.000292	0.00137	CcSEcCtD
Montelukast—Paraesthesia—Etoposide—uterine cancer	0.00029	0.00136	CcSEcCtD
Montelukast—Pancreatitis—Doxorubicin—uterine cancer	0.000289	0.00135	CcSEcCtD
Montelukast—Somnolence—Etoposide—uterine cancer	0.000287	0.00135	CcSEcCtD
Montelukast—Pneumonia—Epirubicin—uterine cancer	0.000286	0.00134	CcSEcCtD
Montelukast—Infestation—Epirubicin—uterine cancer	0.000284	0.00133	CcSEcCtD
Montelukast—Drowsiness—Epirubicin—uterine cancer	0.000284	0.00133	CcSEcCtD
Montelukast—Infestation NOS—Epirubicin—uterine cancer	0.000284	0.00133	CcSEcCtD
Montelukast—Vomiting—Dactinomycin—uterine cancer	0.000284	0.00133	CcSEcCtD
Montelukast—Bronchitis—Doxorubicin—uterine cancer	0.000284	0.00133	CcSEcCtD
Montelukast—Stevens-Johnson syndrome—Epirubicin—uterine cancer	0.000282	0.00132	CcSEcCtD
Montelukast—Rash—Dactinomycin—uterine cancer	0.000282	0.00132	CcSEcCtD
Montelukast—Gastrointestinal disorder—Etoposide—uterine cancer	0.000279	0.00131	CcSEcCtD
Montelukast—Fatigue—Etoposide—uterine cancer	0.000279	0.00131	CcSEcCtD
Montelukast—Neuropathy peripheral—Epirubicin—uterine cancer	0.000278	0.0013	CcSEcCtD
Montelukast—Jaundice—Epirubicin—uterine cancer	0.000277	0.0013	CcSEcCtD
Montelukast—Pain—Etoposide—uterine cancer	0.000276	0.00129	CcSEcCtD
Montelukast—Conjunctivitis—Epirubicin—uterine cancer	0.000276	0.00129	CcSEcCtD
Montelukast—Upper respiratory tract infection—Doxorubicin—uterine cancer	0.000274	0.00128	CcSEcCtD
Montelukast—Hepatobiliary disease—Epirubicin—uterine cancer	0.000269	0.00126	CcSEcCtD
Montelukast—Epistaxis—Epirubicin—uterine cancer	0.000268	0.00125	CcSEcCtD
Montelukast—Sinusitis—Epirubicin—uterine cancer	0.000267	0.00125	CcSEcCtD
Montelukast—Nausea—Dactinomycin—uterine cancer	0.000265	0.00124	CcSEcCtD
Montelukast—Pneumonia—Doxorubicin—uterine cancer	0.000264	0.00124	CcSEcCtD
Montelukast—Gastrointestinal pain—Etoposide—uterine cancer	0.000264	0.00124	CcSEcCtD
Montelukast—Drowsiness—Doxorubicin—uterine cancer	0.000263	0.00123	CcSEcCtD
Montelukast—Infestation NOS—Doxorubicin—uterine cancer	0.000263	0.00123	CcSEcCtD
Montelukast—Infestation—Doxorubicin—uterine cancer	0.000263	0.00123	CcSEcCtD
Montelukast—Stevens-Johnson syndrome—Doxorubicin—uterine cancer	0.000261	0.00122	CcSEcCtD
Montelukast—Neuropathy peripheral—Doxorubicin—uterine cancer	0.000258	0.00121	CcSEcCtD
Montelukast—Urticaria—Etoposide—uterine cancer	0.000257	0.0012	CcSEcCtD
Montelukast—Jaundice—Doxorubicin—uterine cancer	0.000256	0.0012	CcSEcCtD
Montelukast—Rhinitis—Epirubicin—uterine cancer	0.000256	0.0012	CcSEcCtD
Montelukast—Abdominal pain—Etoposide—uterine cancer	0.000256	0.0012	CcSEcCtD
Montelukast—Body temperature increased—Etoposide—uterine cancer	0.000256	0.0012	CcSEcCtD
Montelukast—Conjunctivitis—Doxorubicin—uterine cancer	0.000255	0.0012	CcSEcCtD
Montelukast—Hepatitis—Epirubicin—uterine cancer	0.000255	0.00119	CcSEcCtD
Montelukast—Hypoaesthesia—Epirubicin—uterine cancer	0.000254	0.00119	CcSEcCtD
Montelukast—Pharyngitis—Epirubicin—uterine cancer	0.000253	0.00119	CcSEcCtD
Montelukast—Urinary tract disorder—Epirubicin—uterine cancer	0.000252	0.00118	CcSEcCtD
Montelukast—Connective tissue disorder—Epirubicin—uterine cancer	0.000251	0.00117	CcSEcCtD
Montelukast—Urethral disorder—Epirubicin—uterine cancer	0.00025	0.00117	CcSEcCtD
Montelukast—Hepatobiliary disease—Doxorubicin—uterine cancer	0.000249	0.00116	CcSEcCtD
Montelukast—Epistaxis—Doxorubicin—uterine cancer	0.000248	0.00116	CcSEcCtD
Montelukast—Sinusitis—Doxorubicin—uterine cancer	0.000247	0.00115	CcSEcCtD
Montelukast—Erythema multiforme—Epirubicin—uterine cancer	0.000241	0.00113	CcSEcCtD
Montelukast—Hypersensitivity—Etoposide—uterine cancer	0.000238	0.00112	CcSEcCtD
Montelukast—Cardiac disorder—Epirubicin—uterine cancer	0.000237	0.00111	CcSEcCtD
Montelukast—Rhinitis—Doxorubicin—uterine cancer	0.000237	0.00111	CcSEcCtD
Montelukast—Hepatitis—Doxorubicin—uterine cancer	0.000236	0.00111	CcSEcCtD
Montelukast—Hypoaesthesia—Doxorubicin—uterine cancer	0.000235	0.0011	CcSEcCtD
Montelukast—Pharyngitis—Doxorubicin—uterine cancer	0.000234	0.0011	CcSEcCtD
Montelukast—Urinary tract disorder—Doxorubicin—uterine cancer	0.000233	0.00109	CcSEcCtD
Montelukast—Asthenia—Etoposide—uterine cancer	0.000232	0.00109	CcSEcCtD
Montelukast—Connective tissue disorder—Doxorubicin—uterine cancer	0.000232	0.00109	CcSEcCtD
Montelukast—Urethral disorder—Doxorubicin—uterine cancer	0.000231	0.00108	CcSEcCtD
Montelukast—Immune system disorder—Epirubicin—uterine cancer	0.00023	0.00108	CcSEcCtD
Montelukast—Mediastinal disorder—Epirubicin—uterine cancer	0.00023	0.00108	CcSEcCtD
Montelukast—Pruritus—Etoposide—uterine cancer	0.000229	0.00107	CcSEcCtD
Montelukast—Mental disorder—Epirubicin—uterine cancer	0.000223	0.00105	CcSEcCtD
Montelukast—Erythema multiforme—Doxorubicin—uterine cancer	0.000223	0.00104	CcSEcCtD
Montelukast—Diarrhoea—Etoposide—uterine cancer	0.000221	0.00104	CcSEcCtD
Montelukast—Cardiac disorder—Doxorubicin—uterine cancer	0.000219	0.00103	CcSEcCtD
Montelukast—Dizziness—Etoposide—uterine cancer	0.000214	0.001	CcSEcCtD
Montelukast—Muscle spasms—Epirubicin—uterine cancer	0.000213	0.001	CcSEcCtD
Montelukast—Immune system disorder—Doxorubicin—uterine cancer	0.000213	0.000998	CcSEcCtD
Montelukast—Mediastinal disorder—Doxorubicin—uterine cancer	0.000213	0.000996	CcSEcCtD
Montelukast—Mental disorder—Doxorubicin—uterine cancer	0.000207	0.000968	CcSEcCtD
Montelukast—Vomiting—Etoposide—uterine cancer	0.000206	0.000962	CcSEcCtD
Montelukast—Agitation—Epirubicin—uterine cancer	0.000204	0.000955	CcSEcCtD
Montelukast—Rash—Etoposide—uterine cancer	0.000204	0.000954	CcSEcCtD
Montelukast—Dermatitis—Etoposide—uterine cancer	0.000204	0.000954	CcSEcCtD
Montelukast—Headache—Etoposide—uterine cancer	0.000202	0.000948	CcSEcCtD
Montelukast—Muscle spasms—Doxorubicin—uterine cancer	0.000197	0.000925	CcSEcCtD
Montelukast—Palpitations—Epirubicin—uterine cancer	0.000196	0.000919	CcSEcCtD
Montelukast—Cough—Epirubicin—uterine cancer	0.000194	0.000907	CcSEcCtD
Montelukast—Convulsion—Epirubicin—uterine cancer	0.000192	0.000901	CcSEcCtD
Montelukast—Nausea—Etoposide—uterine cancer	0.000192	0.000899	CcSEcCtD
Montelukast—Myalgia—Epirubicin—uterine cancer	0.000189	0.000885	CcSEcCtD
Montelukast—Arthralgia—Epirubicin—uterine cancer	0.000189	0.000885	CcSEcCtD
Montelukast—Agitation—Doxorubicin—uterine cancer	0.000189	0.000884	CcSEcCtD
Montelukast—Anxiety—Epirubicin—uterine cancer	0.000188	0.000882	CcSEcCtD
Montelukast—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—uterine cancer	0.000188	0.000879	CcSEcCtD
Montelukast—Palpitations—Doxorubicin—uterine cancer	0.000182	0.00085	CcSEcCtD
Montelukast—Oedema—Epirubicin—uterine cancer	0.000181	0.000848	CcSEcCtD
Montelukast—Anaphylactic shock—Epirubicin—uterine cancer	0.000181	0.000848	CcSEcCtD
Montelukast—Infection—Epirubicin—uterine cancer	0.00018	0.000843	CcSEcCtD
Montelukast—Cough—Doxorubicin—uterine cancer	0.000179	0.000839	CcSEcCtD
Montelukast—Convulsion—Doxorubicin—uterine cancer	0.000178	0.000833	CcSEcCtD
Montelukast—Nervous system disorder—Epirubicin—uterine cancer	0.000178	0.000832	CcSEcCtD
Montelukast—Thrombocytopenia—Epirubicin—uterine cancer	0.000177	0.000831	CcSEcCtD
Montelukast—Skin disorder—Epirubicin—uterine cancer	0.000176	0.000824	CcSEcCtD
Montelukast—Arthralgia—Doxorubicin—uterine cancer	0.000175	0.000819	CcSEcCtD
Montelukast—Myalgia—Doxorubicin—uterine cancer	0.000175	0.000819	CcSEcCtD
Montelukast—Anxiety—Doxorubicin—uterine cancer	0.000174	0.000816	CcSEcCtD
Montelukast—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—uterine cancer	0.000174	0.000813	CcSEcCtD
Montelukast—Oedema—Doxorubicin—uterine cancer	0.000168	0.000785	CcSEcCtD
Montelukast—Anaphylactic shock—Doxorubicin—uterine cancer	0.000168	0.000785	CcSEcCtD
Montelukast—Infection—Doxorubicin—uterine cancer	0.000167	0.00078	CcSEcCtD
Montelukast—Musculoskeletal discomfort—Epirubicin—uterine cancer	0.000165	0.000773	CcSEcCtD
Montelukast—Nervous system disorder—Doxorubicin—uterine cancer	0.000164	0.00077	CcSEcCtD
Montelukast—Thrombocytopenia—Doxorubicin—uterine cancer	0.000164	0.000769	CcSEcCtD
Montelukast—Insomnia—Epirubicin—uterine cancer	0.000164	0.000767	CcSEcCtD
Montelukast—Skin disorder—Doxorubicin—uterine cancer	0.000163	0.000763	CcSEcCtD
Montelukast—Paraesthesia—Epirubicin—uterine cancer	0.000163	0.000762	CcSEcCtD
Montelukast—Somnolence—Epirubicin—uterine cancer	0.000161	0.000754	CcSEcCtD
Montelukast—Dyspepsia—Epirubicin—uterine cancer	0.000159	0.000747	CcSEcCtD
Montelukast—Gastrointestinal disorder—Epirubicin—uterine cancer	0.000156	0.000733	CcSEcCtD
Montelukast—Fatigue—Epirubicin—uterine cancer	0.000156	0.000732	CcSEcCtD
Montelukast—Pain—Epirubicin—uterine cancer	0.000155	0.000726	CcSEcCtD
Montelukast—Musculoskeletal discomfort—Doxorubicin—uterine cancer	0.000153	0.000715	CcSEcCtD
Montelukast—Insomnia—Doxorubicin—uterine cancer	0.000152	0.00071	CcSEcCtD
Montelukast—Paraesthesia—Doxorubicin—uterine cancer	0.000151	0.000705	CcSEcCtD
Montelukast—Somnolence—Doxorubicin—uterine cancer	0.000149	0.000698	CcSEcCtD
Montelukast—Gastrointestinal pain—Epirubicin—uterine cancer	0.000148	0.000694	CcSEcCtD
Montelukast—Dyspepsia—Doxorubicin—uterine cancer	0.000148	0.000691	CcSEcCtD
Montelukast—Gastrointestinal disorder—Doxorubicin—uterine cancer	0.000145	0.000678	CcSEcCtD
Montelukast—Fatigue—Doxorubicin—uterine cancer	0.000145	0.000677	CcSEcCtD
Montelukast—Urticaria—Epirubicin—uterine cancer	0.000144	0.000674	CcSEcCtD
Montelukast—Pain—Doxorubicin—uterine cancer	0.000143	0.000671	CcSEcCtD
Montelukast—Body temperature increased—Epirubicin—uterine cancer	0.000143	0.000671	CcSEcCtD
Montelukast—Abdominal pain—Epirubicin—uterine cancer	0.000143	0.000671	CcSEcCtD
Montelukast—Gastrointestinal pain—Doxorubicin—uterine cancer	0.000137	0.000642	CcSEcCtD
Montelukast—Hypersensitivity—Epirubicin—uterine cancer	0.000133	0.000625	CcSEcCtD
Montelukast—Urticaria—Doxorubicin—uterine cancer	0.000133	0.000624	CcSEcCtD
Montelukast—Abdominal pain—Doxorubicin—uterine cancer	0.000133	0.000621	CcSEcCtD
Montelukast—Body temperature increased—Doxorubicin—uterine cancer	0.000133	0.000621	CcSEcCtD
Montelukast—Asthenia—Epirubicin—uterine cancer	0.00013	0.000609	CcSEcCtD
Montelukast—Pruritus—Epirubicin—uterine cancer	0.000128	0.0006	CcSEcCtD
Montelukast—Diarrhoea—Epirubicin—uterine cancer	0.000124	0.000581	CcSEcCtD
Montelukast—Hypersensitivity—Doxorubicin—uterine cancer	0.000124	0.000578	CcSEcCtD
Montelukast—Asthenia—Doxorubicin—uterine cancer	0.00012	0.000563	CcSEcCtD
Montelukast—Dizziness—Epirubicin—uterine cancer	0.00012	0.000561	CcSEcCtD
Montelukast—Pruritus—Doxorubicin—uterine cancer	0.000119	0.000555	CcSEcCtD
Montelukast—Vomiting—Epirubicin—uterine cancer	0.000115	0.000539	CcSEcCtD
Montelukast—Diarrhoea—Doxorubicin—uterine cancer	0.000115	0.000537	CcSEcCtD
Montelukast—Rash—Epirubicin—uterine cancer	0.000114	0.000535	CcSEcCtD
Montelukast—Dermatitis—Epirubicin—uterine cancer	0.000114	0.000534	CcSEcCtD
Montelukast—Headache—Epirubicin—uterine cancer	0.000114	0.000532	CcSEcCtD
Montelukast—Dizziness—Doxorubicin—uterine cancer	0.000111	0.000519	CcSEcCtD
Montelukast—Nausea—Epirubicin—uterine cancer	0.000108	0.000504	CcSEcCtD
Montelukast—Vomiting—Doxorubicin—uterine cancer	0.000107	0.000499	CcSEcCtD
Montelukast—Rash—Doxorubicin—uterine cancer	0.000106	0.000495	CcSEcCtD
Montelukast—Dermatitis—Doxorubicin—uterine cancer	0.000106	0.000495	CcSEcCtD
Montelukast—Headache—Doxorubicin—uterine cancer	0.000105	0.000492	CcSEcCtD
Montelukast—Nausea—Doxorubicin—uterine cancer	9.96e-05	0.000466	CcSEcCtD
Montelukast—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP11A1—uterine cancer	6.15e-05	0.00902	CbGpPWpGaD
Montelukast—CYP2C8—Oxidation by Cytochrome P450—CYP11A1—uterine cancer	6.07e-05	0.0089	CbGpPWpGaD
Montelukast—ALOX5—Metabolism of lipids and lipoproteins—AKR1B1—uterine cancer	6.07e-05	0.0089	CbGpPWpGaD
Montelukast—ALOX5—Metabolism of lipids and lipoproteins—STAR—uterine cancer	6.07e-05	0.0089	CbGpPWpGaD
Montelukast—PTGS1—Phase 1 - Functionalization of compounds—CYP19A1—uterine cancer	5.68e-05	0.00833	CbGpPWpGaD
Montelukast—CYSLTR1—Endothelins—HRAS—uterine cancer	5.47e-05	0.00802	CbGpPWpGaD
Montelukast—CYP2C9—Arachidonic acid metabolism—AKR1C3—uterine cancer	5.47e-05	0.00802	CbGpPWpGaD
Montelukast—CYP2A6—Phase 1 - Functionalization of compounds—CYP19A1—uterine cancer	5.37e-05	0.00787	CbGpPWpGaD
Montelukast—SLCO2B1—Transmembrane transport of small molecules—ABCC9—uterine cancer	5.36e-05	0.00786	CbGpPWpGaD
Montelukast—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP11A1—uterine cancer	5.01e-05	0.00734	CbGpPWpGaD
Montelukast—CYP2A6—NRF2 pathway—NFE2L2—uterine cancer	4.99e-05	0.00732	CbGpPWpGaD
Montelukast—CYP2C8—Phase 1 - Functionalization of compounds—CYP11A1—uterine cancer	4.99e-05	0.00731	CbGpPWpGaD
Montelukast—CYP2C9—Oxidation by Cytochrome P450—CYP11A1—uterine cancer	4.94e-05	0.00724	CbGpPWpGaD
Montelukast—CYSLTR1—Endothelins—AKT1—uterine cancer	4.83e-05	0.00708	CbGpPWpGaD
Montelukast—CYP2A6—NRF2 pathway—GPX3—uterine cancer	4.76e-05	0.00698	CbGpPWpGaD
Montelukast—CYP2C8—Metapathway biotransformation—AKR1B10—uterine cancer	4.7e-05	0.00688	CbGpPWpGaD
Montelukast—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP19A1—uterine cancer	4.53e-05	0.00663	CbGpPWpGaD
Montelukast—CYP2C8—Oxidation by Cytochrome P450—CYP19A1—uterine cancer	4.47e-05	0.00655	CbGpPWpGaD
Montelukast—ALOX5—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	4.46e-05	0.00653	CbGpPWpGaD
Montelukast—CYP2C8—Metapathway biotransformation—AKR1B1—uterine cancer	4.37e-05	0.0064	CbGpPWpGaD
Montelukast—PTGS1—Biological oxidations—CYP11A1—uterine cancer	4.1e-05	0.00601	CbGpPWpGaD
Montelukast—CYP2C9—Phase 1 - Functionalization of compounds—CYP11A1—uterine cancer	4.06e-05	0.00595	CbGpPWpGaD
Montelukast—CYP2A6—Biological oxidations—CYP11A1—uterine cancer	3.88e-05	0.00568	CbGpPWpGaD
Montelukast—PTGS1—Selenium Micronutrient Network—MTHFR—uterine cancer	3.88e-05	0.00568	CbGpPWpGaD
Montelukast—CYP2C9—Metapathway biotransformation—AKR1B10—uterine cancer	3.82e-05	0.0056	CbGpPWpGaD
Montelukast—ALOX5—Metabolism—NDUFB11—uterine cancer	3.74e-05	0.00548	CbGpPWpGaD
Montelukast—ALOX5—Metabolism—SRD5A2—uterine cancer	3.74e-05	0.00548	CbGpPWpGaD
Montelukast—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP19A1—uterine cancer	3.69e-05	0.0054	CbGpPWpGaD
Montelukast—CYP2C8—Phase 1 - Functionalization of compounds—CYP19A1—uterine cancer	3.67e-05	0.00538	CbGpPWpGaD
Montelukast—PTGS1—Metabolism of lipids and lipoproteins—SRD5A2—uterine cancer	3.64e-05	0.00534	CbGpPWpGaD
Montelukast—CYP2C9—Oxidation by Cytochrome P450—CYP19A1—uterine cancer	3.64e-05	0.00533	CbGpPWpGaD
Montelukast—ALOX5—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	3.63e-05	0.00532	CbGpPWpGaD
Montelukast—CYP2C9—Metapathway biotransformation—AKR1B1—uterine cancer	3.56e-05	0.00521	CbGpPWpGaD
Montelukast—ALOX5—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	3.43e-05	0.00503	CbGpPWpGaD
Montelukast—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP11A1—uterine cancer	3.3e-05	0.00484	CbGpPWpGaD
Montelukast—CYSLTR1—Class A/1 (Rhodopsin-like receptors)—CCL2—uterine cancer	3.27e-05	0.00479	CbGpPWpGaD
Montelukast—CYP3A4—Oxidation by Cytochrome P450—CYP11A1—uterine cancer	3.26e-05	0.00478	CbGpPWpGaD
Montelukast—CYP2C8—Metapathway biotransformation—AKR1C1—uterine cancer	3.21e-05	0.0047	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—AKR1B10—uterine cancer	3.14e-05	0.0046	CbGpPWpGaD
Montelukast—CYP2A6—Fluoropyrimidine Activity—TP53—uterine cancer	3.05e-05	0.00447	CbGpPWpGaD
Montelukast—PTGS1—Selenium Micronutrient Network—CCL2—uterine cancer	3.03e-05	0.00445	CbGpPWpGaD
Montelukast—PTGS1—Biological oxidations—CYP19A1—uterine cancer	3.02e-05	0.00442	CbGpPWpGaD
Montelukast—CYP3A4—Tryptophan metabolism—CYP19A1—uterine cancer	3.01e-05	0.0044	CbGpPWpGaD
Montelukast—CYP2C9—Phase 1 - Functionalization of compounds—CYP19A1—uterine cancer	2.99e-05	0.00438	CbGpPWpGaD
Montelukast—CYP2A6—Biological oxidations—CYP19A1—uterine cancer	2.85e-05	0.00418	CbGpPWpGaD
Montelukast—CYP2C8—Metapathway biotransformation—GPX3—uterine cancer	2.82e-05	0.00412	CbGpPWpGaD
Montelukast—CYSLTR1—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—uterine cancer	2.8e-05	0.00411	CbGpPWpGaD
Montelukast—ALOX5—Metabolism—AKR1B1—uterine cancer	2.7e-05	0.00396	CbGpPWpGaD
Montelukast—ALOX5—Metabolism—STAR—uterine cancer	2.7e-05	0.00396	CbGpPWpGaD
Montelukast—CYP3A4—Phase 1 - Functionalization of compounds—CYP11A1—uterine cancer	2.68e-05	0.00392	CbGpPWpGaD
Montelukast—ALOX5—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	2.67e-05	0.00392	CbGpPWpGaD
Montelukast—CYP2C8—Biological oxidations—CYP11A1—uterine cancer	2.65e-05	0.00388	CbGpPWpGaD
Montelukast—PTGS1—Metabolism of lipids and lipoproteins—STAR—uterine cancer	2.63e-05	0.00386	CbGpPWpGaD
Montelukast—PTGS1—Metabolism of lipids and lipoproteins—AKR1B1—uterine cancer	2.63e-05	0.00386	CbGpPWpGaD
Montelukast—CYP2C8—Metapathway biotransformation—CYP11A1—uterine cancer	2.61e-05	0.00383	CbGpPWpGaD
Montelukast—CYP2C9—Metapathway biotransformation—AKR1C1—uterine cancer	2.61e-05	0.00382	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—RNF43—uterine cancer	2.6e-05	0.00381	CbGpPWpGaD
Montelukast—CYSLTR1—Class A/1 (Rhodopsin-like receptors)—CXCL8—uterine cancer	2.59e-05	0.00379	CbGpPWpGaD
Montelukast—CYP3A4—Metapathway biotransformation—AKR1B10—uterine cancer	2.52e-05	0.0037	CbGpPWpGaD
Montelukast—CYSLTR1—GPCR ligand binding—CCL2—uterine cancer	2.49e-05	0.00365	CbGpPWpGaD
Montelukast—CYSLTR1—G alpha (q) signalling events—PIK3CA—uterine cancer	2.48e-05	0.00363	CbGpPWpGaD
Montelukast—CYP2C8—Metapathway biotransformation—AKR1C3—uterine cancer	2.47e-05	0.00362	CbGpPWpGaD
Montelukast—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—uterine cancer	2.43e-05	0.00356	CbGpPWpGaD
Montelukast—CYSLTR1—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—uterine cancer	2.41e-05	0.00353	CbGpPWpGaD
Montelukast—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—uterine cancer	2.4e-05	0.00351	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—INHBA—uterine cancer	2.38e-05	0.00348	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism of lipids and lipoproteins—SRD5A2—uterine cancer	2.35e-05	0.00345	CbGpPWpGaD
Montelukast—CYP3A4—Metapathway biotransformation—AKR1B1—uterine cancer	2.34e-05	0.00344	CbGpPWpGaD
Montelukast—CYP2C9—Metapathway biotransformation—GPX3—uterine cancer	2.29e-05	0.00336	CbGpPWpGaD
Montelukast—CYSLTR1—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—uterine cancer	2.22e-05	0.00325	CbGpPWpGaD
Montelukast—CYP2C9—Biological oxidations—CYP11A1—uterine cancer	2.16e-05	0.00316	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—AKR1C1—uterine cancer	2.14e-05	0.00314	CbGpPWpGaD
Montelukast—CYP2C9—Metapathway biotransformation—CYP11A1—uterine cancer	2.13e-05	0.00312	CbGpPWpGaD
Montelukast—ALOX5—Metabolism—POLD1—uterine cancer	2.12e-05	0.00311	CbGpPWpGaD
Montelukast—CYSLTR1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—uterine cancer	2.05e-05	0.003	CbGpPWpGaD
Montelukast—CYP2C9—Metapathway biotransformation—AKR1C3—uterine cancer	2.01e-05	0.00294	CbGpPWpGaD
Montelukast—ALOX5—Metabolism—AKR1C1—uterine cancer	1.99e-05	0.00291	CbGpPWpGaD
Montelukast—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—uterine cancer	1.97e-05	0.00289	CbGpPWpGaD
Montelukast—CYSLTR1—GPCR ligand binding—CXCL8—uterine cancer	1.97e-05	0.00289	CbGpPWpGaD
Montelukast—CYP2C8—Biological oxidations—CYP19A1—uterine cancer	1.95e-05	0.00286	CbGpPWpGaD
Montelukast—PTGS1—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	1.93e-05	0.00283	CbGpPWpGaD
Montelukast—CYP2C8—Metapathway biotransformation—CYP19A1—uterine cancer	1.92e-05	0.00282	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism of lipids and lipoproteins—SRD5A2—uterine cancer	1.91e-05	0.00281	CbGpPWpGaD
Montelukast—ALOX5—Metabolism—RRM2—uterine cancer	1.77e-05	0.00259	CbGpPWpGaD
Montelukast—CYP3A4—Metapathway biotransformation—AKR1C1—uterine cancer	1.72e-05	0.00252	CbGpPWpGaD
Montelukast—ALOX5—Metabolism—DCN—uterine cancer	1.72e-05	0.00252	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism of lipids and lipoproteins—AKR1B1—uterine cancer	1.7e-05	0.00249	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism of lipids and lipoproteins—STAR—uterine cancer	1.7e-05	0.00249	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—AKR1C3—uterine cancer	1.65e-05	0.00242	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—NDUFB11—uterine cancer	1.62e-05	0.00238	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—SRD5A2—uterine cancer	1.62e-05	0.00238	CbGpPWpGaD
Montelukast—ALOX5—Metabolism—CYP11A1—uterine cancer	1.62e-05	0.00237	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—PGR—uterine cancer	1.61e-05	0.00235	CbGpPWpGaD
Montelukast—CYP2C9—Biological oxidations—CYP19A1—uterine cancer	1.59e-05	0.00233	CbGpPWpGaD
Montelukast—PTGS1—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	1.58e-05	0.00231	CbGpPWpGaD
Montelukast—CYP2C9—Metapathway biotransformation—CYP19A1—uterine cancer	1.57e-05	0.00229	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—NDUFB11—uterine cancer	1.53e-05	0.00225	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—SRD5A2—uterine cancer	1.53e-05	0.00225	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—YWHAE—uterine cancer	1.53e-05	0.00225	CbGpPWpGaD
Montelukast—ALOX5—Metabolism—AKR1C3—uterine cancer	1.53e-05	0.00224	CbGpPWpGaD
Montelukast—CYP3A4—Metapathway biotransformation—GPX3—uterine cancer	1.51e-05	0.00221	CbGpPWpGaD
Montelukast—PTGS1—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	1.49e-05	0.00218	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—FBXW7—uterine cancer	1.47e-05	0.00215	CbGpPWpGaD
Montelukast—CYP3A4—Biological oxidations—CYP11A1—uterine cancer	1.42e-05	0.00208	CbGpPWpGaD
Montelukast—CYP3A4—Metapathway biotransformation—CYP11A1—uterine cancer	1.4e-05	0.00206	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism of lipids and lipoproteins—STAR—uterine cancer	1.38e-05	0.00203	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism of lipids and lipoproteins—AKR1B1—uterine cancer	1.38e-05	0.00203	CbGpPWpGaD
Montelukast—CYP3A4—Metapathway biotransformation—AKR1C3—uterine cancer	1.32e-05	0.00194	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—STK11—uterine cancer	1.28e-05	0.00188	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling by GPCR—CCL2—uterine cancer	1.28e-05	0.00187	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	1.25e-05	0.00183	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—SOCS3—uterine cancer	1.2e-05	0.00176	CbGpPWpGaD
Montelukast—ALOX5—Metabolism—STK11—uterine cancer	1.19e-05	0.00174	CbGpPWpGaD
Montelukast—ALOX5—Metabolism—CYP19A1—uterine cancer	1.19e-05	0.00174	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—AKR1B1—uterine cancer	1.17e-05	0.00172	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—STAR—uterine cancer	1.17e-05	0.00172	CbGpPWpGaD
Montelukast—PTGS1—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	1.16e-05	0.0017	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—CDKN2B—uterine cancer	1.15e-05	0.00169	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—IGF1R—uterine cancer	1.12e-05	0.00164	CbGpPWpGaD
Montelukast—ALOX5—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	1.12e-05	0.00164	CbGpPWpGaD
Montelukast—CYSLTR1—GPCR downstream signaling—CXCL8—uterine cancer	1.11e-05	0.00163	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—AKR1B1—uterine cancer	1.11e-05	0.00162	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—STAR—uterine cancer	1.11e-05	0.00162	CbGpPWpGaD
Montelukast—ALOX5—Metabolism of lipids and lipoproteins—EP300—uterine cancer	1.07e-05	0.00156	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—SMAD3—uterine cancer	1.05e-05	0.00154	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—SRD5A2—uterine cancer	1.05e-05	0.00154	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—NDUFB11—uterine cancer	1.05e-05	0.00154	CbGpPWpGaD
Montelukast—CYP3A4—Biological oxidations—CYP19A1—uterine cancer	1.05e-05	0.00153	CbGpPWpGaD
Montelukast—CYP3A4—Metapathway biotransformation—CYP19A1—uterine cancer	1.03e-05	0.00151	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	1.02e-05	0.00149	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	1.02e-05	0.00149	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling by GPCR—CXCL8—uterine cancer	1.01e-05	0.00148	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—FGFR2—uterine cancer	1e-05	0.00147	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	9.61e-06	0.00141	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—POLD1—uterine cancer	9.2e-06	0.00135	CbGpPWpGaD
Montelukast—ALOX5—Metabolism—MTHFR—uterine cancer	8.95e-06	0.00131	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—POLD1—uterine cancer	8.7e-06	0.00127	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—AKR1C1—uterine cancer	8.61e-06	0.00126	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—ESR1—uterine cancer	8.58e-06	0.00126	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—SRD5A2—uterine cancer	8.53e-06	0.00125	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—NDUFB11—uterine cancer	8.53e-06	0.00125	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	8.28e-06	0.00121	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—AKR1C1—uterine cancer	8.14e-06	0.00119	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling by GPCR—NRAS—uterine cancer	8.11e-06	0.00119	CbGpPWpGaD
Montelukast—ALOX5—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	7.88e-06	0.00116	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	7.82e-06	0.00115	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—RRM2—uterine cancer	7.67e-06	0.00112	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—AKR1B1—uterine cancer	7.58e-06	0.00111	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—STAR—uterine cancer	7.58e-06	0.00111	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—CCL2—uterine cancer	7.55e-06	0.00111	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	7.49e-06	0.0011	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—DCN—uterine cancer	7.45e-06	0.00109	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—RRM2—uterine cancer	7.25e-06	0.00106	CbGpPWpGaD
Montelukast—CYSLTR1—GPCR downstream signaling—PIK3CA—uterine cancer	7.06e-06	0.00103	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—DCN—uterine cancer	7.04e-06	0.00103	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—CYP11A1—uterine cancer	7.02e-06	0.00103	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling by GPCR—KRAS—uterine cancer	6.98e-06	0.00102	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—CYP11A1—uterine cancer	6.64e-06	0.000972	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—AKR1C3—uterine cancer	6.63e-06	0.000971	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling by GPCR—PIK3CA—uterine cancer	6.41e-06	0.00094	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—ERBB2—uterine cancer	6.3e-06	0.000923	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—AKR1C3—uterine cancer	6.27e-06	0.000918	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—AKR1B1—uterine cancer	6.17e-06	0.000903	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—STAR—uterine cancer	6.17e-06	0.000903	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	6.09e-06	0.000893	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—CXCL8—uterine cancer	5.97e-06	0.000875	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—POLD1—uterine cancer	5.94e-06	0.000871	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling by GPCR—HRAS—uterine cancer	5.93e-06	0.000869	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—CDKN1B—uterine cancer	5.83e-06	0.000854	CbGpPWpGaD
Montelukast—CYSLTR1—GPCR downstream signaling—AKT1—uterine cancer	5.77e-06	0.000845	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—SRD5A2—uterine cancer	5.62e-06	0.000824	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—NDUFB11—uterine cancer	5.62e-06	0.000824	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—AKR1C1—uterine cancer	5.56e-06	0.000815	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—CTNNB1—uterine cancer	5.51e-06	0.000807	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—PTEN—uterine cancer	5.37e-06	0.000787	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling by GPCR—AKT1—uterine cancer	5.24e-06	0.000768	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—STK11—uterine cancer	5.16e-06	0.000756	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—CYP19A1—uterine cancer	5.16e-06	0.000756	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—EP300—uterine cancer	5.12e-06	0.00075	CbGpPWpGaD
Montelukast—ALOX5—Metabolism—PTEN—uterine cancer	4.98e-06	0.000729	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—RRM2—uterine cancer	4.96e-06	0.000726	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—STK11—uterine cancer	4.88e-06	0.000715	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—CYP19A1—uterine cancer	4.88e-06	0.000715	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—VEGFA—uterine cancer	4.85e-06	0.000711	CbGpPWpGaD
Montelukast—PTGS1—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	4.85e-06	0.00071	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—POLD1—uterine cancer	4.84e-06	0.000709	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—DCN—uterine cancer	4.81e-06	0.000705	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—NRAS—uterine cancer	4.79e-06	0.000702	CbGpPWpGaD
Montelukast—ALOX5—Metabolism—EP300—uterine cancer	4.75e-06	0.000695	CbGpPWpGaD
Montelukast—PTGS1—Metabolism of lipids and lipoproteins—EP300—uterine cancer	4.62e-06	0.000677	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—CYP11A1—uterine cancer	4.53e-06	0.000664	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—AKR1C1—uterine cancer	4.53e-06	0.000663	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—AKR1C3—uterine cancer	4.28e-06	0.000627	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—KRAS—uterine cancer	4.12e-06	0.000604	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—AKR1B1—uterine cancer	4.07e-06	0.000596	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—STAR—uterine cancer	4.07e-06	0.000596	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—RRM2—uterine cancer	4.03e-06	0.000591	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—DCN—uterine cancer	3.92e-06	0.000574	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—MTHFR—uterine cancer	3.88e-06	0.000568	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—PIK3CA—uterine cancer	3.79e-06	0.000555	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—CYP11A1—uterine cancer	3.69e-06	0.00054	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—MTHFR—uterine cancer	3.67e-06	0.000537	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—TP53—uterine cancer	3.66e-06	0.000537	CbGpPWpGaD
Montelukast—ALOX5—Metabolism—PIK3CA—uterine cancer	3.51e-06	0.000514	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—HRAS—uterine cancer	3.5e-06	0.000513	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—AKR1C3—uterine cancer	3.48e-06	0.00051	CbGpPWpGaD
Montelukast—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	3.42e-06	0.000501	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—STK11—uterine cancer	3.33e-06	0.000489	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—CYP19A1—uterine cancer	3.33e-06	0.000489	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—POLD1—uterine cancer	3.19e-06	0.000467	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	3.13e-06	0.000459	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—AKT1—uterine cancer	3.09e-06	0.000453	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism of lipids and lipoproteins—EP300—uterine cancer	2.99e-06	0.000437	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—AKR1C1—uterine cancer	2.98e-06	0.000437	CbGpPWpGaD
Montelukast—ALOX5—Metabolism—AKT1—uterine cancer	2.87e-06	0.00042	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—CYP19A1—uterine cancer	2.71e-06	0.000398	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—STK11—uterine cancer	2.71e-06	0.000398	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—RRM2—uterine cancer	2.66e-06	0.00039	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—DCN—uterine cancer	2.58e-06	0.000378	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	2.55e-06	0.000373	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—MTHFR—uterine cancer	2.51e-06	0.000367	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—CYP11A1—uterine cancer	2.43e-06	0.000356	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism of lipids and lipoproteins—EP300—uterine cancer	2.43e-06	0.000356	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—AKR1C3—uterine cancer	2.3e-06	0.000337	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	2.21e-06	0.000324	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—PTEN—uterine cancer	2.16e-06	0.000316	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—EP300—uterine cancer	2.06e-06	0.000302	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—PTEN—uterine cancer	2.04e-06	0.000299	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—MTHFR—uterine cancer	2.04e-06	0.000299	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—EP300—uterine cancer	1.95e-06	0.000285	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	1.8e-06	0.000263	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—STK11—uterine cancer	1.79e-06	0.000262	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—CYP19A1—uterine cancer	1.79e-06	0.000262	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—PIK3CA—uterine cancer	1.52e-06	0.000223	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—PIK3CA—uterine cancer	1.44e-06	0.000211	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—PTEN—uterine cancer	1.39e-06	0.000204	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—MTHFR—uterine cancer	1.35e-06	0.000197	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—EP300—uterine cancer	1.33e-06	0.000195	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—AKT1—uterine cancer	1.24e-06	0.000182	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—AKT1—uterine cancer	1.18e-06	0.000172	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—PTEN—uterine cancer	1.13e-06	0.000166	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—EP300—uterine cancer	1.08e-06	0.000159	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—PIK3CA—uterine cancer	9.83e-07	0.000144	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—AKT1—uterine cancer	8.03e-07	0.000118	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—PIK3CA—uterine cancer	8e-07	0.000117	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—PTEN—uterine cancer	7.48e-07	0.00011	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—EP300—uterine cancer	7.14e-07	0.000105	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—AKT1—uterine cancer	6.54e-07	9.58e-05	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—PIK3CA—uterine cancer	5.28e-07	7.73e-05	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—AKT1—uterine cancer	4.31e-07	6.32e-05	CbGpPWpGaD
